Magenau, J., Pawarode, A., Buck, T., Jones, D., Kato, K., Frame, D., … Mineishi, S. (2009). Conditioning with Clofarabine and Busulfan X 4 (CloBu4) For Non-Remission Hematologic Malignancies Including Aml Is Well Tolerated, Facilitates Secure Engraftment, And Exhibits Significant Anti-Tumor Activity. In Biology of Blood and Marrow Transplantation (Vol. 15, pp. 104–104). Elsevier BV. https://doi.org/10.1016/j.bbmt.2008.12.321

Magenau, J., A. Pawarode, T. Buck, D. Jones, K. Kato, D. Frame, L. Kujawski, et al. “Conditioning with Clofarabine and Busulfan X 4 (CloBu4) For Non-Remission Hematologic Malignancies Including Aml Is Well Tolerated, Facilitates Secure Engraftment, And Exhibits Significant Anti-Tumor Activity.” In Biology of Blood and Marrow Transplantation, 15:104–104. Elsevier BV, 2009. https://doi.org/10.1016/j.bbmt.2008.12.321.

Magenau J, Pawarode A, Buck T, Jones D, Kato K, Frame D, et al. Conditioning with Clofarabine and Busulfan X 4 (CloBu4) For Non-Remission Hematologic Malignancies Including Aml Is Well Tolerated, Facilitates Secure Engraftment, And Exhibits Significant Anti-Tumor Activity. In: Biology of Blood and Marrow Transplantation. Elsevier BV; 2009. p. 104–104.

Magenau, J., et al. “Conditioning with Clofarabine and Busulfan X 4 (CloBu4) For Non-Remission Hematologic Malignancies Including Aml Is Well Tolerated, Facilitates Secure Engraftment, And Exhibits Significant Anti-Tumor Activity.” Biology of Blood and Marrow Transplantation, vol. 15, no. 2, Elsevier BV, 2009, pp. 104–104. Crossref, doi:10.1016/j.bbmt.2008.12.321.

Magenau J, Pawarode A, Buck T, Jones D, Kato K, Frame D, Kujawski L, Erba HP, Khaled Y, Peres EM, Krijanovski OI, Reddy P, Kitko C, Choi S, Yanik G, Braun T, Ferrara JLM, Levine JE, Mineishi S. Conditioning with Clofarabine and Busulfan X 4 (CloBu4) For Non-Remission Hematologic Malignancies Including Aml Is Well Tolerated, Facilitates Secure Engraftment, And Exhibits Significant Anti-Tumor Activity. Biology of Blood and Marrow Transplantation. Elsevier BV; 2009. p. 104–104.